Bath psoralen plus ultraviolet‐A photochemotherapy for chronic graft‐versus‐host disease: a retrospective cohort study

Abstract

BackgroundChronic graft‐versus‐host disease is a severe complication of allogeneic stem cell and bone marrow transplantation. First‐line immunosuppressive agents, such as steroids, are used to prevent this disease; however, they have multiple side effects. Therefore, bath psoralen plus ultraviolet‐A (PUVA) is an alternative second‐line treatment. This study aimed to evaluate the clinical efficacy of bath PUVA for managing chronic graft‐versus‐host disease.MethodsThis retrospective, case–control study included 14 patients with extensive cutaneous chronic graft‐versus‐host disease, resistant to systemic corticosteroid, treated with bath PUVA. Major and partial responses were defined as clinical improvements of >70% and 50–70%, respectively. We analyzed the graft‐versus‐host disease clinical presentation and timing after allogeneic stem cell and bone marrow transplantation, bath PUVA doses, background diseases, additional treatments, and adverse effects.ResultsWe observed eight major (three lichenoid and five sclerodermatoid) and six partial (three lichenoid and three sclerodermatoid) responses after a mean of 28 treatment sessions. After 6 to 25 months, four of the eight patients with sclerodermatoid lesions and all those with lichenoid lesions experienced relapse but responded to additional treatment cycles.ConclusionsBath PUVA is well‐tolerated and effective for extensive cutaneous chronic graft‐versus‐host disease. It allows rapid tapering of adjuvant immunosuppressants; however, most patients require prolonged maintenance phototherapy.